Sohn Y M, Lee J S, Park J H, Poerschke G, Eves K, Gress J, Kuter B
Department of Pediatrics, Yongdong Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Southeast Asian J Trop Med Public Health. 2004 Dec;35(4):954-8.
We evaluated the CR326F strain (VAQTA) derived hepatitis A vaccine in Korean children and adolescents >2 years of age to consider a future immunization program. In our study, the pediatric two-dose regimen of VAQTA was found to be generally well tolerated and resulted in 100% (95% CI 94.8, 100.0) seroconversion after 2 doses. Immunizing children with the HAV vaccine routinely should be considered in South Korea, particularly in areas where recent outbreaks have occurred.
我们在2岁以上的韩国儿童和青少年中评估了CR326F株（VAQTA）甲型肝炎疫苗，以考虑未来的免疫规划。在我们的研究中，发现VAQTA的儿科两剂方案总体耐受性良好，两剂后血清转化率达100%（95%CI 94.8, 100.0）。韩国应考虑对儿童常规接种甲型肝炎疫苗，特别是在近期发生过疫情的地区。
